Bringing a probiotic product to market in Canada begins with determining how the finished product will be classified. Depending on its composition, dosage form, intended use, claims and overall presentation, a probiotic may be regulated as a Natural Health Product (NHP), a conventional food or a supplemented food. A probiotic microorganism intended for use in food may also require assessment under Canada’s Novel Food framework where the strain does not have a history of safe use as food or where another characteristic of the product meets the definition of a novel food.
These classifications affect considerably more than the route to market. They determine the applicable requirements for product authorization, scientific evidence, strain characterization, viable microorganism levels, stability, manufacturing and importing, health claims and Canadian labelling. Novel strains and differentiated health claims can introduce additional evidence requirements and may require clinical research to support the intended commercial use.
For manufacturers, an effective Canadian market-access strategy therefore needs to consider the finished product, microorganism, evidence package, claims, manufacturing process and commercial supply chain together. This article examines these requirements across the principal Canadian regulatory pathways for probiotics.
Probiotics occupy an unusual position within the Canadian regulatory framework because the presence of a live microorganism does not, by itself, determine how a finished product will be regulated.
A probiotic supplied in a capsule, a probiotic incorporated into yogurt and a functional beverage containing probiotics alongside vitamins or other supplemental ingredients may contain similar microorganisms but be subject to materially different regulatory requirements.
The first stage of Canadian market access is therefore classification of the finished product. Its formulation, dosage form, intended conditions of use, target population, representations made to consumers and overall presentation need to be considered together.
For an NHP, market access can involve a Product Licence Application (PLA), issuance of a Natural Product Number (NPN), compliance with the Natural Health Products Regulations and, where applicable, Health Canada’s Probiotics Monograph. For foods, the regulatory analysis shifts to the Food and Drugs Act and Food and Drug Regulations, including the requirements governing conventional foods, supplemented foods, probiotic health claims and novel foods. Food businesses may separately be subject to licensing, preventive control and traceability requirements under the Safe Food for Canadians Act (SFCA) and Safe Food for Canadians Regulations (SFCR).
The following table provides an overview of how these regulatory frameworks can apply.
| Regulatory route | When it may apply | Primary regulatory considerations | Market authorization / requirements | Key evidence considerations |
| Natural Health Product (NHP) | A probiotic regulated as an NHP, commonly in supplement-style dosage forms and represented for health purposes | Natural Health Products Regulations; Probiotics Monograph where applicable; formulation, strain, dose and claims | PLA and NPN; applicable NHP site licensing and GMP requirements | Strain identity and characterization; safety; CFU/dose; viability and stability; evidence supporting proposed conditions of use; additional evidence where the product or claims fall outside the monograph |
| Conventional food | A probiotic incorporated into a conventional food such as certain yogurts, fermented foods or beverages | Food and Drug Regulations; food composition and labelling; probiotic representations and health claims | No NPN; product must comply with applicable Canadian food requirements | Eligibility for accepted probiotic claims; strain identity; viable CFU through shelf life; substantiation for claims outside Health Canada’s accepted framework |
| Supplemented food | A permitted prepackaged food containing one or more supplemental ingredients, potentially alongside probiotics | Division 29 of the Food and Drug Regulations; Lists of Permitted Supplemented Food Categories and Supplemental Ingredients | Generally no individual pre-market authorization where the product complies with the supplemented-food framework; specific composition and labelling requirements apply | Probiotic evidence and claim requirements continue to apply separately; supplemental ingredients must meet their respective conditions of use |
| Novel food | A food containing a microorganism without a history of safe use as food, or a food meeting another part of the Novel Food definition | Division 28 of the Food and Drug Regulations | Mandatory pre-market safety assessment before sale | Detailed characterization and safety evidence; requirements are case-specific and additional data may be requested, including human evidence where needed to address relevant evidence gaps |
| SFCA/SFCR food compliance | Applies as an additional regulatory layer to businesses conducting activities such as importing food or preparing food for interprovincial trade | Safe Food for Canadians Act and Regulations | SFC licence where required; preventive controls, PCP and traceability requirements as applicable | Primarily food-safety, establishment and import compliance rather than substantiation of probiotic efficacy |
These categories are not entirely independent of one another. NHP versus food classification establishes the principal regulatory framework for the finished product, while other requirements can operate within or alongside that classification. A supplemented food remains a food, for example, and the Novel Food provisions may still need to be considered when a microorganism or another aspect of the food meets the applicable definition.
Similarly, the SFCA and SFCR do not provide an alternative product-classification route to an NPN. They govern activities within the food supply chain, including importing and certain interprovincial activities. Product authorization, ingredient status, establishment licensing and importing may therefore need to be addressed separately as part of the same Canadian commercialization strategy.
Health Canada’s Natural Health Products Regulations define a probiotic as a monoculture or mixed culture of live microorganisms that benefits the microbiota indigenous to humans. Probiotic products falling within the NHP framework require pre-market product authorization through a PLA. Once authorized, the product receives an eight-digit NPN that must appear on the label.
For established probiotic microorganisms and uses, Health Canada’s Probiotics Monograph, updated April 24, 2026, provides the regulatory basis for certain applications. The monograph establishes requirements relating to microorganism identity, strain characterization, quantities, uses, doses, risk information, storage and specifications.
An applicant referencing the monograph is attesting that the product complies with the applicable conditions and specifications. This includes requirements relating to species identification, strain characterization, CFU quantification, virulence assessment, antimicrobial resistance, virulence factors and toxigenicity.
The monograph should not be interpreted as a general authorization for any product containing a microorganism commonly described as probiotic. Eligibility depends on the particular microorganism, formulation, dose, conditions of use and claims.
The current monograph also excludes non-viable forms, including heat-killed and thermostabilized microorganisms, from the monograph and compendial application process. Manufacturers developing products based on inactivated microorganisms or microbial components consequently need to assess those products separately rather than assuming that the probiotic monograph provides an applicable route.
The complete formulation is relevant when determining how an NHP application can proceed.
Health Canada’s current monograph contains specific conditions for combinations involving probiotics, prebiotics, enzymes and other medicinal ingredients. Certain dry probiotic preparations can be combined with ingredients from other monographs under specified conditions, while non-dry products and combinations involving enzymes can be treated differently depending on their formulation and claims.
Liquid probiotic and prebiotic combinations provide another example. Under the current monograph, the application class can differ depending on whether a prebiotic claim is made and whether the prebiotic is referenced in the brand name. Products that fall outside the applicable compendial conditions may require a Class III application and additional supporting evidence.
For manufacturers, regulatory planning therefore cannot stop at confirming that an individual strain appears in the Probiotics Monograph. The commercial formulation, dosage form, accompanying ingredients and proposed claims need to be evaluated together.
The regulatory assessment of a probiotic extends beyond identification at the species level. Microorganisms within the same species can differ genetically and phenotypically, and those differences can affect safety, biological activity and the relevance of supporting scientific evidence.
Health Canada’s current Probiotics Monograph requires current and validated species identification together with strain characterization. Its specifications address phenotypic and genotypic characterization and include genome-based approaches to confirming microorganism identity.
Safety characterization also extends beyond taxonomy. The monograph addresses antimicrobial or antifungal resistance, the genetic basis and transferability of atypical resistance, susceptibility to therapeutic antimicrobial agents, virulence factors and toxigenic activity.
These requirements have a direct relationship to evidence substantiation. Evidence generated using one strain cannot necessarily be extrapolated to another strain belonging to the same species, particularly where the evidence is intended to substantiate a measurable health benefit. Health Canada’s probiotic guidance has historically emphasized the need for strain-specific evidence where appropriate and the importance of demonstrating that the strain identified in an application corresponds to the strain evaluated in the supporting evidence.
A manufacturer developing a proprietary probiotic should therefore establish strain identity and characterization early in product development. Changes to the strain after the evidence program has begun can affect the applicability of safety, efficacy and clinical data already generated.
Unlike many conventional ingredients, the amount of probiotic added during manufacture does not by itself establish the amount that will be delivered to the consumer. Viable microorganisms can decline over time, making stability and shelf-life controls integral to the product specification.
Health Canada’s Probiotics Monograph requires quantities to be expressed in colony forming units (CFU). For medicinal ingredients covered by the applicable general provisions of the monograph, the current minimum total daily amount is \(1.0 \times 10^7\) CFU, although particular strains and uses can have different or higher dosage requirements.
Individual strain quantities must be included on the PLA, product label and finished-product specifications in CFU per dosage unit. Gravimetric or volumetric quantities are not accepted as substitutes for viable counts.
The monograph also requires stability and viability measures capable of ensuring that at least 80% of the declared label quantity remains at the end of shelf life.
This has practical implications for formulation and manufacturing. Moisture, oxygen, temperature, packaging, storage, the physical characteristics of the dosage form and interactions with other ingredients can affect viability. A formulation may therefore contain an appropriate probiotic strain and dose at manufacture but fail to support the proposed label if viable counts decline excessively before expiry.
Combination products can add further complexity. Prebiotics, enzymes and other ingredients may alter the environment in which the probiotic must remain stable. Shelf-life strategy should therefore be developed using the commercial formulation and packaging rather than assuming that stability demonstrated for the isolated microorganism will automatically transfer to the finished product.
The commercial label for an authorized probiotic NHP must comply with the Natural Health Products Regulations and correspond to the terms of its product licence.
Health Canada’s amended NHP labelling requirements include a standardized Product Facts Table (PFT). Compliance has been extended for all NHPs until June 21, 2028, so products may continue using the previous labelling requirements during the transition period. Depending on the packaging configuration, mandatory information includes elements such as the brand name, product number, dosage form, medicinal ingredients and quantities, recommended use or purpose, directions, risk information, storage information and non-medicinal ingredients.
For probiotic products, manufacturing materials can introduce additional considerations. Cryoprotectants or other substances intentionally added to maintain microorganism stability or viability may need to be declared as non-medicinal ingredients. Culture media can also create allergen considerations where the microorganism has been exposed to priority allergens or their derivatives.
Labelling should therefore be developed alongside formulation, licensing and quality assessment. Waiting until an NPN has been obtained to develop the Canadian label can expose discrepancies between the authorized formulation, specifications, risk information and proposed commercial artwork.
A probiotic incorporated into a conventional food does not require an NPN simply because it contains a live microorganism. It instead falls within Canada’s food regulatory framework and must comply with the applicable provisions of the Food and Drugs Act and Food and Drug Regulations.
However, the word “probiotic” is itself regulated in the food context. Health Canada considers “probiotic” and similar representations to be implied health claims. The term should not appear on a food without an accepted or appropriately substantiated health claim relating to the viable microorganism contained in the product.
Health Canada’s current framework identifies accepted non-strain-specific representations such as “probiotic that naturally forms part of the gut flora” and “provides live microorganisms that contribute to healthy gut flora.” These claims can be used under specified conditions for eligible microorganisms.
For the listed eligible microorganisms, the food must contain at least \(1.0 \times 10^9\) CFU per serving of stated size, maintained throughout the product’s shelf life. The identity of the microorganism must be declared using scientific nomenclature identifying genus and species together with strain identity, and the amount present at the end of shelf life must be declared in CFU per serving.
The food matrix itself becomes relevant to compliance because viable microorganisms must survive at the required level through expiry. Factors such as the physicochemical characteristics of the food, pH, storage environment and packaging material can affect survival.
The conventional-food pathway therefore retains many of the scientific issues encountered with probiotic NHPs—strain identity, viable quantity, stability and evidence—but applies them under a different regulatory framework and with different thresholds and claim requirements.
Manufacturers seeking to make claims outside the established framework need to consider the evidence supporting the specific strain and proposed health effect.
For certain live microorganism strains seeking the applicable non-strain-specific claims outside the established eligible list, Health Canada’s current evidence criteria call for a minimum of two independent, well-designed, good-quality human intervention studies on the specific strain demonstrating a consistent beneficial health effect related to the digestive tract.
Evidence should also support that the strain was derived from human intestinal microflora or can establish itself, survive and grow temporarily in the digestive tract. Validated in vitro digestion models can provide supporting information but are not sufficient as the sole evidence base.
Strain-specific claims require substantiation of the particular beneficial health effect attributed to that strain. The amount required to achieve the effect must be maintained throughout shelf life.
The clinical development strategy should therefore be established with the intended Canadian claim in mind. A well-conducted study does not automatically provide useful regulatory evidence if the strain, dose, population, endpoint or formulation does not correspond to the commercial product and proposed representation.
Canada’s Supplemented Foods Regulations create another important consideration for functional food formulations, particularly beverages and similar products containing probiotics alongside vitamins, minerals, amino acids or other substances added for supplemental purposes.
A supplemented food is a prepackaged food containing one or more supplemental ingredients. Division 29 of the Food and Drug Regulations establishes the regulatory framework, supported by incorporated lists specifying permitted supplemented-food categories, permitted supplemental ingredients and applicable conditions of use.
The addition of a probiotic does not automatically turn a conventional food into a supplemented food. A conventional food can contain a probiotic without falling under Division 29. Conversely, a product containing a probiotic together with one or more supplemental ingredients may fall within the supplemented-food framework if the applicable regulatory criteria are met.
Supplemented foods meeting the regulations, incorporated lists and other applicable provisions of the Food and Drug Regulations can generally access the market without obtaining an individual Health Canada pre-market authorization solely because they are supplemented foods.
The probiotic and supplemental components nevertheless need to be assessed independently within the finished product. Compliance with Division 29 does not remove the requirements associated with representing a microorganism as probiotic.
Supplemented foods have a distinct Canadian label architecture. Applicable products require a Supplemented Food Facts table (SFFt) rather than a conventional Nutrition Facts table and, depending on the supplemental ingredients and their quantities, may require a Supplemented Food Caution Identifier (SFCI) and prescribed cautionary statements.
These requirements operate alongside the general food-labelling provisions and any requirements associated with probiotic representations.
A supplemented beverage making a probiotic claim, for example, may therefore need to satisfy Division 29 requirements concerning its supplemental ingredients while also meeting Health Canada’s probiotic conditions concerning strain identification, CFU declaration, shelf-life viability and claim substantiation.
This is one reason formulation and labelling should be assessed together. The addition, removal or adjustment of an ingredient can change the regulatory requirements applicable to the finished product and potentially alter the mandatory label.
A separate pre-market assessment may arise where a probiotic microorganism is intended for use in food but is considered novel.
Division 28 of the Food and Drug Regulations defines a novel food to include a substance, including a microorganism, that does not have a history of safe use as food. The definition also captures foods produced through previously unapplied processes that cause a major change and certain foods derived from genetically modified plants, animals or microorganisms.
This framework is particularly relevant to manufacturers developing proprietary or emerging probiotic strains for which there is limited history of consumption in the food supply.
Novel foods are subject to mandatory pre-market safety assessment before they may be sold in Canada. Where Health Canada’s assessment concludes that the novel food is safe, the manufacturer or importer receives the applicable written notification, commonly referred to as a letter of no objection.
A novel food that has completed the applicable assessment may subsequently be used in foods, including supplemented foods, subject to the remaining regulatory requirements.
Novelty should therefore be assessed early in the development of a new probiotic food. Establishing a formulation, manufacturing process, claims strategy and commercial launch plan before determining the regulatory status of the microorganism can result in substantial redevelopment if a Novel Food assessment is subsequently required.
The Novel Food analysis should not be restricted to asking whether the microorganism’s species has previously been consumed.
Health Canada’s framework also addresses foods manufactured using processes not previously applied to the food where the process causes a major change. Its probiotic food guidance identifies novel delivery technologies, including microencapsulation used to deliver viable microorganisms, as an issue that may need to be considered under Division 28.
The assessment may therefore need to consider the specific strain, its history of food use, production organism, manufacturing process, processing technology, delivery system and resulting characteristics of the finished food.
This is increasingly relevant as microbiome science moves beyond traditional fermented-food organisms toward proprietary strains, new microbial species and more sophisticated manufacturing and delivery technologies.
The evidence required for a Novel Food assessment is determined by the characteristics of the microorganism, the nature of the novelty and the proposed food use. The assessment is therefore case-specific rather than a standardized clinical-data requirement for every novel probiotic.
For a microbial ingredient, the evidence package can require extensive characterization and information concerning identity, manufacturing, microbiological characteristics, history and exposure, intended use and safety. Health Canada may request additional information where the available evidence does not adequately resolve a safety question.
For well-characterized microorganisms with substantial relevant history and scientific literature, existing information may provide much of the necessary evidence. Proprietary or genuinely novel strains can present a different situation because published studies may concern related species or strains rather than the microorganism proposed for commercialization.
Where meaningful evidence gaps remain, additional non-clinical or human evidence may be necessary. Clinical research can also serve a second commercial objective where the manufacturer intends to establish a differentiated strain-specific health benefit.
These objectives should be identified before study design begins. A study intended primarily to establish safety may require different endpoints, population characteristics and statistical considerations than one designed to substantiate a particular health effect. Where both regulatory objectives can appropriately be addressed within a development program, early coordination can reduce duplication and improve the usefulness of the resulting evidence.
For probiotics, evidence should be evaluated in the context of the microorganism and product to which it will ultimately be applied.
Health Canada’s food framework explicitly requires strain-specific human evidence for certain probiotic claims and requires the effective microorganism quantity to remain present through the end of shelf life. The NHP framework similarly places substantial emphasis on strain characterization, dose, viable quantity and supporting evidence.
A clinical program therefore needs to account for the relationship between the investigational material and the commercial formulation. Relevant variables can include strain identity, dose, manufacturing process, viable count, formulation matrix, delivery technology, storage conditions and target population.
The issue becomes more complex for multi-strain products and products combining probiotics with prebiotics or other functional ingredients. Evidence for an individual strain does not necessarily establish the effect of a combination, while formulation changes that reduce viability may prevent the commercial product from delivering the dose evaluated clinically.
Clinical and regulatory planning should consequently begin before the final evidence program is commissioned rather than attempting to adapt completed research to a different commercial product afterward.
Once a probiotic has been classified as a conventional or supplemented food and the applicable ingredient, evidence and claim requirements have been established, manufacturers and importers need to determine their obligations under the Safe Food for Canadians Act and Safe Food for Canadians Regulations.
The SFCR regulates food-business activities rather than providing another product-classification pathway.
Importers, in most cases, require an SFC licence to import food into Canada. They are responsible for ensuring that imported food meets Canadian requirements and that foreign suppliers prepare, store and transport the food under appropriate food-safety controls.
Applicable businesses must implement preventive controls and, in many cases, maintain a written preventive control plan (PCP). The SFCR also establishes applicable traceability and recordkeeping requirements.
Businesses manufacturing, processing, treating, preserving, grading, packaging or labelling food for interprovincial trade or export must similarly determine their applicable licensing and preventive-control obligations.
A foreign probiotic manufacturer entering Canada may therefore need to address several regulatory layers. The product itself must first be compliant as a conventional or supplemented food, including any applicable Novel Food and health-claim requirements. The commercial supply chain must then be structured to satisfy the relevant Canadian import, licensing, preventive-control and traceability requirements.
An SFC licence does not provide authorization for an otherwise non-compliant probiotic ingredient, novel microorganism or health claim.
Probiotic NHPs operate under a different establishment-licensing framework.
Under the Natural Health Products Regulations, Canadian businesses performing regulated activities such as manufacturing, packaging, labelling or importing NHPs must comply with the applicable site-licensing and Good Manufacturing Practices requirements. Imported NHPs therefore require both an appropriate product-authorization strategy and a compliant route through the Canadian supply chain.
This distinction can become important for companies with multiple probiotic products. A business may have one probiotic marketed as an NHP and another incorporated into a food, with different regulatory frameworks governing product authorization, importing, manufacturing controls and labelling.
Portfolio-level market access should consequently begin with classification of individual products rather than assuming that one Canadian regulatory or importing arrangement applies to every probiotic SKU.
The consequences of classification become particularly visible when the Canadian label is developed.
An NHP label must match the authorized product licence and applicable labelling requirements, including the NPN. The amended requirements add a standardized Product Facts Table, but it is not yet mandatory during the transition period ending June 21, 2028. A conventional probiotic food follows the food-labelling framework, including the Nutrition Facts table and applicable ingredient and allergen declarations. A supplemented probiotic food follows the supplemented-food labelling framework, including the SFFt and, where triggered, cautionary information.
Probiotic claims introduce additional requirements for foods. Health Canada’s current guidance requires applicable scientific nomenclature and strain identity to be declared and requires the amount of microorganism present at the end of shelf life to be stated in CFU per serving.
A foreign label therefore cannot simply be translated and repurposed for Canada. A U.S. dietary supplement, functional beverage or probiotic food may have a different Canadian classification, different permissible ingredients, different claim requirements and a substantially different mandatory label architecture.
The regulatory assessment should precede final Canadian artwork.
The appropriate route to market can often be established efficiently when the regulatory assessment is conducted early enough in product development.
For an established probiotic NHP that conforms to Health Canada’s monograph, the pathway may be relatively straightforward. A formulation or claim outside the monograph can require additional evidence and a different PLA strategy. A conventional food may qualify for one of Health Canada’s accepted probiotic claims if the microorganism, viable quantity and other conditions are satisfied. A food containing supplemental ingredients introduces Division 29 requirements. A novel strain or qualifying novel process can add a separate pre-market safety assessment before a food can be commercialized.
These requirements then need to remain aligned with product development. Strain characterization needs to support the identity used in the regulatory dossier and evidence. Stability needs to demonstrate the required viable quantity through the proposed shelf life. Clinical research needs to evaluate a strain, dose and population relevant to the intended claim. Manufacturing needs to preserve the characteristics of the microorganism and finished product. The Canadian label needs to accurately reflect the resulting authorization, evidence and regulatory classification.
Considering these requirements only after the commercial formulation has been finalized can lead to avoidable reformulation, additional studies, revised claims, packaging changes or delays to market entry. Integrating regulatory, quality and clinical strategy earlier allows the requirements of the Canadian pathway to inform development decisions while there is still flexibility to make changes.
At dicentra, we support organizations developing and commercializing probiotics across Natural Health Product, conventional food, supplemented food, Novel Food and clinical development pathways in Canada.
Our integrated regulatory, quality and clinical teams can support manufacturers with:
For probiotic products, these activities are closely connected. The strain identified in the regulatory submission should correspond to the strain supported by the scientific and clinical evidence; the commercial formulation and manufacturing process need to preserve the relevant characteristics of that strain; and stability data need to demonstrate that the finished product can deliver the declared viable quantity throughout its shelf life.
For novel strains or products pursuing differentiated health claims, regulatory and clinical development can also be planned together. Early assessment of the existing evidence can identify whether additional characterization, safety data or human clinical evidence will be needed and allow any required studies to be designed around the intended Canadian product, dose, population and claims.
dicentra’s combination of regulatory consulting, quality expertise and full-service CRO capabilities allows these requirements to be addressed as part of a coordinated Canadian market-access strategy rather than as separate activities late in development.
Contact dicentra to discuss bringing a probiotic to market in Canada, including product classification, NPN licensing, conventional and supplemented foods, Novel Food submissions, Canadian labelling and claims, quality requirements and clinical evidence development.